The proteasome inhibitor MG132 induces apoptosis in human pancreatic cancer cells

Oncology Reports

Volumn 14, Issue 6, 2005, Pages 1635-1638

  Wente, Moritz N ^a,b   Eibl, Guido ^b   Reber, Howard A ^b   Friess, Helmut ^a   Büchler, Markus W ^a   Hines, Oscar J ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; Pancreatic cancer; Proteasome inhibition

Indexed keywords

BENZYLOXYCARBONYLLEUCYL LEUCYL LEUCINE ALDEHYDE; BENZYLOXYCARBONYLLEUCYL-LEUCYL-LEUCINE ALDEHYDE; CYSTEINE PROTEINASE INHIBITOR; LEUPEPTIN;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; METABOLISM; NUCLEOSOME; PANCREAS TUMOR; PATHOLOGY; TIME; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYSTEINE PROTEINASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; LEUPEPTINS; NUCLEOSOMES; PANCREATIC NEOPLASMS; TIME FACTORS;

EID: 33644689390     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.14.6.1635     Document Type: Article

References (19)

1. Ciechanover A: The ubiquitin-proteasome proteolytic pathway. Cell 79: 13-21, 1994.
2. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S and Elliott PJ: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 59: 2615-2622, 1999. (Pubitemid 29269108)
3. WAFI/CIP1, and induction of apoptosis are independent markers of proteasome inhibition. Leukemia 14: 1276-1283, 2000.
4. Rajkumar SV, Richardson PG, Hideshima T and Anderson KC: Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23: 630-639, 2005. (Pubitemid 46224241)
5. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP and Anderson KC: A phase II study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348: 2609-2617, 2003. (Pubitemid 36741588)
6. Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, Vogelzang NJ and Stadler WM: Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol 22: 115-119, 2004. (Pubitemid 41095122)
7. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, Sabbatini P, Miller V, Hensley ML, Pezzulli S, Canales C, Daud A and Spriggs DR: A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 8: 2505-2511, 2002. (Pubitemid 34856332)
8. Maki RG, Kraft AS, Scheu K, Yamada J, Wadier S, Antonescu CR, Wright JJ and Schwartz GK: A multicenter phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer 103: 1431-1438, 2005. (Pubitemid 40410740)
9. Rock KL, Gramm C, Rothstein L, Clark K, Stein R, Dick L, Hwang D and Goldberg AL: Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78: 761-771, 1994. (Pubitemid 24294452)
10. Orlowski RZ: The role of the ubiquitin-proteasome pathway in apoptosis. Cell Death Differ 6: 303-313, 1999.
11. Banerjee D and Liefshitz A: Potential of the proteasome inhibitor MG132 as an anticancer agent, alone and in combination. Anticancer Res 21: 3941-3948, 2001.
12. McDade TP, Perugini RA, Vittimberga FJ and Callery MP: Ubiquitin-proteasome inhibition enhances apoptosis of human pancreatic cancer cells. Surgery 126: 371-377, 1999. (Pubitemid 29382805)
13. Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, Adams J and Callery MP: 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 82: 110-122, 2001.
14. Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, Abbruzzese JL, Elliott P, Adams J and McConkey DJ: Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Therl: 1243-1253, 2002.
15. Golab J, Stoklosa T, Czajka A, Dabrowska A, Jakobisiak M, Zagozdzon R, Wojcik C, Marczak M and Wilk S: Synergistic antitumor effects of a selective proteasome inhibitor and TNF in mice. Anticancer Res 20: 1717-1722, 2000.
16. Lin ZP, Boiler YC, Amer SM, Russell RL, Pacelli KA, Patierno SR and Kennedy KA: Prevention of brefeldin A-induced resistance to teniposide by the proteasome inhibitor MG-132: involvement of NF-kappaB activation in drug resistance. Cancer Res 58: 3059-3065, 1998. (Pubitemid 28335087)
17. Delic J, Masdehors P, Omura S, Cosset JM, Dumont J, Binet JL and Magdelenat H: The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis. Br J Cancer 77: 1103-1107, 1998. (Pubitemid 28116281)
18. Bold RJ, Virudachalam S and McConkey DJ: Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 100: 11-17, 2001. (Pubitemid 32802698)
19. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T and Anderson KC: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101: 2377-2380, 2003. (Pubitemid 36302084)